Targets › STAT3
3 programs from 3 companies in 6 trials: 3 Phase 2, 3 Phase 1; Oncology; next expected readout Dec 2027.
Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors. Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene. (UniProt, P40763)
Open in Phaseline: the race on STAT3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Northwestern University | WP1066 STAT3 inhibitor | STAT3 | Phase 2 | Glioblastoma, IDH-Wildtype | Dec 2027 |
| AstraZeneca | Danvatirsen STAT-3 mRNA 3'UTR antisense inhibitor | STAT3 | Phase 2 | Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced Colorectal Carcinoma; AML/MDS | – |
| University of Colorado, Denver | NT219 IRS1/2 and STAT3 inhibitor | IRS1, IRS2, STAT3 | Phase 1 | Head and Neck Cancer | Feb 2030 |
Non-Small Cell Lung Cancer (1) Metastatic Non-Small Cell Lung Cancer (NSCLC) (1) Advanced Colorectal Carcinoma (1) AML/MDS (1) Glioblastoma, IDH-Wildtype (1) Head and Neck Cancer (1)
small molecule (2), mixed (1)
AstraZeneca (1) Northwestern University (1) University of Colorado, Denver (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.